Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

• Mary L Disis,
• John B Liao,
• Doreen M Higgins,
• Jennifer S Childs,
• Sasha E Stanton,
• Anna V Tinker,
• William R Gwin,
• Renata R Urban,
• Katie M Hitchcock-Bernhardt,
• Andrew L Coveler,
• Hania N Shakalia,
• Ron E Swensen,
• Tanya A Wahl,
• Richard G Ancheta,
• Kathryn F McGonigle,
• James Y Dai,
• Barbara A Goff

Affiliations

Mary L Disis

University of Washington School of Medicine, Seattle, Washington, USA

John B Liao

University of Washington School of Medicine, Seattle, Washington, USA

Doreen M Higgins

University of Washington School of Medicine, Seattle, Washington, USA

Jennifer S Childs

University of Washington School of Medicine, Seattle, Washington, USA

Sasha E Stanton

Providence Cancer Center, Portland, Oregon, USA

Anna V Tinker

BC Cancer Agency, Vancouver, British Columbia, Canada

William R Gwin

University of Washington School of Medicine, Seattle, Washington, USA

Renata R Urban

University of Washington School of Medicine, Seattle, Washington, USA

Katie M Hitchcock-Bernhardt

University of Washington School of Medicine, Seattle, Washington, USA

Andrew L Coveler

University of Washington School of Medicine, Seattle, Washington, USA

Hania N Shakalia

University of Washington School of Medicine, Seattle, Washington, USA

Ron E Swensen

Valley Medical Center, Renton, Washington, USA

Tanya A Wahl

Swedish Medical Center, Seattle, Washington, USA

Richard G Ancheta

Kaiser Permanente, Seattle, Washington, USA

Kathryn F McGonigle

University of Washington School of Medicine, Seattle, Washington, USA

James Y Dai

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Barbara A Goff

University of Washington School of Medicine, Seattle, Washington, USA